[Combined application of magnesium-aspartate-cardioplegia and general hypothermia in aortic valve replacement (author's transl)].
The surgical results of two similar groups of patients are compared in whom aortic valve replacement was performed utilizing magnesium-aspartate-cardioplegia combined with mild (group A = 71 patients) and profound (group B = 69 patients) hypothermia, respectively. Mortality was 5.6% in group A and 4.3% in group B. Two deaths in group A were due to a severe low cardiac output syndrome, three patients required continuous inotropic circulatory support during the early postoperative course. There was no low cardiac output in group B, no patient required inotropic support. Profound body cooling (esophageal temperature 25 degrees C) and hypothermic injection cardioplegia with magnesium-aspartate provide efficient myocardial protection up to 60 minutes of anoxia.
D001021:Aortic Valve; D001145:Arrhythmias, Cardiac / Q000150:complications; D001224:Aspartic Acid; D006324:Heart Arrest, Induced / Q000379:methods*; D006350:Heart Valve Prosthesis; D006801:Humans; D007036:Hypothermia, Induced; D008274:Magnesium; D013997:Time Factors
D001224:Aspartic Acid; D008274:Magnesium
Kombinierte Anwendung der Magnesium-Aspartat-Kardioplegie und allgemeinen Hypothermie beim Aortenklappenersatz.